EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Ravulizumab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial

Jonathan Barratt, Youssef M K Farag, Kara Rice, Tobin J Cammett, Lesley A Inker, Hernán Trimarchi, Annette Bruchfeld, Hiddo J L Heerspink iD, Adrian Liew, Kevin Carroll, Hong Zhang, Sayna Norouzi und 13 weitere

New England Journal of Medicine · 12.11.2026 · 395 (19) · 1921-1931

DOI: 10.1056/nejmoa2607544 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 12.11.2026. Verfasst von Jonathan Barratt und 24 weiteren Autor:innen. Beteiligte Einrichtung: University of Leicester, Leicester, United Kingdom. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Complement Inactivating Agents, Glomerulonephritis, IGA, Proteinuria. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Alexion, AstraZeneca Rare Disease.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedComplement Inactivating AgentsGlomerulonephritis, IGAProteinuriaAdultFemaleHumansMaleMiddle AgedCreatinineDouble-Blind MethodGlomerular Filtration RateInfusions, IntravenousTreatment Outcome

Substanzen

Antibodies, Monoclonal, HumanizedComplement Inactivating AgentsCreatinineravulizumab

Autor:innen und Institutionen

  • University of Leicester, Leicester, United Kingdom.
  • Clinical Development, Alexion, AstraZeneca Rare Disease, Boston.
  • Biostatistics, Alexion, AstraZeneca Rare Disease, Boston.
  • Translational Biomarker Research, Alexion, AstraZeneca Rare Disease, New Haven, CT.
  • Tufts Medical Center, Boston.
  • Nephrology Service, Hospital Británico de Buenos Aires, Buenos Aires.

ORCID-Profile: Hiddo J L Heerspink

Förderung

  • Alexion, AstraZeneca Rare Disease

Zitieren

APA

Barratt, J., Farag, Y. M. K., Rice, K., Cammett, T. J., Inker, L. A., Trimarchi, H., Bruchfeld, A., Heerspink, H. J. L., Liew, A., Carroll, K., Zhang, H., Norouzi, S., Hou, S., Park, S., Pérez Valdivia, M. Á., Radhakrishnan, J., Suzuki, Y., Schneider, B., Marsala, J., …, & I CAN Trial Group (2026). Ravulizumab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial. New England Journal of Medicine, 395(19), 1921-1931. https://doi.org/10.1056/nejmoa2607544

Vancouver

Barratt J, Farag YMK, Rice K, Cammett TJ, Inker LA, Trimarchi H, et al. Ravulizumab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial. New England Journal of Medicine. 2026;395(19):1921-1931. doi:10.1056/nejmoa2607544

BibTeX
@article{Barratt2026,
  author = {Barratt, Jonathan and Farag, Youssef M K and Rice, Kara and Cammett, Tobin J and Inker, Lesley A and Trimarchi, Hernán and Bruchfeld, Annette and Heerspink, Hiddo J L and Liew, Adrian and Carroll, Kevin and Zhang, Hong and Norouzi, Sayna and Hou, Shuang and Park, Sehoon and Pérez Valdivia, Miguel Ángel and Radhakrishnan, Jai and Suzuki, Yusuke and Schneider, Bonnie and Marsala, John and Carrillo-Infante, Cynthia and Lake, Stephen L and Singh, Ajay K and Nolan, Stephen and Lafayette, Richard A and I CAN Trial Group, I CAN Trial Group},
  title = {Ravulizumab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {395},
  number = {19},
  pages = {1921--1931},
  doi = {10.1056/nejmoa2607544}
}
Kostenlos starten →